Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-MAGE-A3 TCR Gene Therapy for Metastatic Cancer
NCT02153905Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jul 2014
- Primary completion
- Sep 2018
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of MAGE-3 antigen specific T cells in metastatic cancer, melanoma, renal cell carcinoma (RCC), breast cancer, Cervical Cancer (CC), sponsored by National Cancer Institute. Started Jul 2014; status: terminated.
02
Drugs
MAGE-3 antigen specific T cells
03
Conditions
metastatic cancermelanomarenal cell carcinoma (RCC)breast cancerCervical Cancer (CC)
Beyond the preview
Go deeper on NCT02153905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02153905.